Aravive — Investor Presentation (November 2022)
38 slides from Aravive's investor presentation, Nov 29, 2022
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation November 2022 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements “This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to fature trends, events, results of operations, financial candtion or other matters. Forward-looking statements generally che statements that are
Slide 3: Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors
Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors ¢ GASG6/AXL signaling drives metastasis and drug-resistance. ARAV is the only company targeting GASS. Wealth of preciinical studies demonstrate abilty to combine with common standards of care to allow access to alarge tot
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors Sesto ttansgeinend ltd Le Pista Pat contane nD, OABT Semtoe MD Ray HO.CPA tt Se MD. Board of Drectors a J ay S J a x A Paro, mO. iHoohe, MD. Sadek Gallckyre PRO. OABT eho ows creda “YGenmab PACIRA IKINNATE pie @weonore egkERYX Akebia Kreannn Bo BMD IR Pi
Slide 5: Aravive Pipeline - Late Stage with Phase Data in Mid-2023
Aravive Pipeline - Late Stage with Phase 3 Data in Mid-2023 Opportunity for Expansion into Additional Indications and Drug Combinations Batiraxcept {ramet capita yearend Patan Restart FastTrackDesignation in US. Ovarian Cancer ze Topo datamiduzs SES B eteaeeanes aa Car Co Rena 1. Aadtonl mare data t
Slide 6: GAS6/AXL Pathway and Batiraxcept
¢°9 aravive @ GAS6/AXL Pathway and Batiraxcept
Slide 7: GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors
GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors’ GAS6 is a survival switch in tumor cells but not essential in normal tissues’, which lowers the potential for side effects + GAS6/AXL pathway mediates metastasis + GAS6 and AXL expressed by tumor and tumor-associated stromal cells to pro
Slide 8: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in 270% of ovarian, pancreatic, breast, kidney, and uterine cancers" “Clinically, the expression of GAS6 and TAM receptors always predicts poorprognosis"” ‘+ Hao et ak 2017. AKL shighy expressed in ovary-derve tumors a
Slide 9: Effective Oncology Treatment Requires Targeting Both Non-metastatic and Metastatic Tumor Cells
Effective Oncology Treatment Requires Targeting Both Non- metastatic and Metastatic Tumor Cells Batiraxcept specifically targets metastatic tumor cells + Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells ~ Human tumors display epithel
Slide 10: Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor
Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor Improves on shortcomings of other approaches for potent and selective inhibition of the AXLIGAS6 pathway Ani-AXLor ant-GAS6 Antibody Batioxcopt- Decoy AXL Receptor ‘Baiaxcopt mimics AXL to bind and op yer pe ei SLE EAH ciaasoneeini tte ec
Slide 11: Batiraxcept: High Affinity AXL Decoy Protein
Batiraxcept: High Affinity AXL Decoy Protein Inhibits the GAS6/AXL Pathway by Sequestering the GAS6 Ligand Modified AXL-Fe fusion protein engineered Proprietary biomarker assay for stability and very high affinity for GAS6 for serum GAS6 + ~200-fold greater affinity for GAS6 than the native» _Batira
Slide 12: Dosing Strategy Varies by Indication
Dosing Strategy Varies by Indication Batiraxcept exposure correlates with anti-tumor activity + Knockout data and GLP program did not identify DLT + Traditional MTD or DLT approach for identification of Inffal Jocusion S indications with: RP2D not appropriate for batiraxcept due to its = High unmet
Slide 13: ~$3B in Global Revenue Potential in PROC, Renal and Pancreatic
~$3B in Global Revenue Potential in PROC, Renal and Pancreatic* PROC Represents the Most Near-term Opportunity $3B Peak Potential for all 4 Indications Estimated Treatable Patients PDAC + 37.5K (USA) + 46K (EU4/UK) PROC + 4K bev naive (USA) + 5.5K bev naive (EU4/UK) + Bev-experienced patients - 50%
Slide 14: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
¢°9 aravive @ Batiraxcept: Platinum- Resistant Ovarian Cancer (PROC)
Slide 15: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies No observed dose-limiting toxicities up to 20 mg/kg Phase 1a single ascending dose and repeat dose study in healthy volunteers 43 subjects participated; 42 dosed Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs N
Slide 16: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC Modeling Identified RP2D of 15 mg/kg for PROC + Exposure-response relationship identified by unsupervised computer analysis Efficacy Data for Pationts Receiving 10 mg/kg and 15 — Statistically significant relationship be
Slide 17: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3'+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3" Line of Therapy have Progressive Disease by their First CT Scan' FSO HH OGG RRS vw
Slide 18: Batiraxcept + Chemo - Better Response than Chemo Monotherapy
Batiraxcept + Chemo - Better Response than Chemo Monotherapy Phase 1b Results Compared to Literature These Tumors Expected to be Dependent on the GAS6/AXL Pathway Chemotherapy Alone Batiraxcept + Chemotherapy" Patients with ‘on pad <3mo Platinum o FreeInterval == = (rr) .— oo = |_| | ar a ae ae 9 (e
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicarTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging e
Slide 20: Market Research Suggests Batiraxcept Would Fill an Unmet Need (PROC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm To see this level of safety with the “The all-comers data is helpful to improved efficacy is impressive ~ know, but the bev-naive data is | certainly would use this product. quite tr
Slide 21: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
¢°3 aravive +) Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) Population: + Pb: 26 patients + P2: 55 patients (currently enrolling) + Histologically confirmed metastatic ecRCC and progressed on/after a front-line treatment regimen + Excluded patients previously treated with cabozantinib
Slide 23: P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib
P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib 15 mg/kg P1b Ps Safety SEGRE (N=16) ( Batiraxcept-Related Deaths 0 o Grade 3 Adverse Events (AEs), 5 (19.2%) 3(18.8%) 2 (20%) related to Batiraxcept Events: HTN(x2), Events: HTN (x2), Events: Diarrhea, (No Grade 4 or 5 AEs relate
Slide 24: P1b ccRCC: Clinical Activity by Prior VEGF-TKI Status
P1b ccRCC: Clinical Activity by Prior VEGF-TKI Status Designated Fast Track by FDA for patients who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies (e
Slide 25: P1b ccRCC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
P1b ccRCC: Pretreatment Serum sAXL/GASG is a Potential Biomarker with 100% Negative Predictability Best Response All Pb Patients Pib 15mg/kg Pb 20 mg/kg (n=25)" (n=16) PR for Patients with low sAXLIGAS6. O15 (0%) 014 (0%) Confirmed PR for Patients with high aetna 14/20 (55%) 8/12 (67%) 3/8 (38%) 9-m
Slide 26: Anticipated Batiraxcept Phase 2/3 Trial Design in ccRCC
Anticipated Batiraxcept Phase 2/3 Trial Design in ccRCC FDA Recommendation: Integrated P2/S study with interim analyses to look at futility in the biomarker low population and ORR or potential accelerated approval with PFS endpoint for full approval. Full protocol and statistical plan in preparation
Slide 27: Market Research Suggests Batiraxcept Would Fill an Unmet Need (ccRCC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current ccRCC Treatment Paradigm "The upside efficacy would be If this product actually achieves practice-changing in 2L... | this upside efficacy, | would would offer it fo most of the definitely wait to use cabo
Slide 28: Batiraxcept: Pancreatic Adenocarcinoma
¢3 aravive S Batiraxcept: Pancreatic Adenocarcinoma =» ©
Slide 29: Phase 1b Design in 1L Pancreatic Adenocarcinoma
Phase 1b Design in 1L Pancreatic Adenocarcinoma (NCT04983407) Patients with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Lead-inPhase Dose Escalation Batiraxcept Endpoints: 18 malig on days 1& 15 alkgbaticaxcep
Slide 30: Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease
Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study Batiraxcept-Related Deaths 0 6 (29%) Grade 3 Adverse Events (AEs), related to Batiraxcept Events: Back Pain, Dizziness, Fatigue, Muscular (No Grade 4 or 5 AEs related to Batiraxcept) Geena ‘AES Leadin
Slide 31: Anti-Tumor Activity from Phase 1b PDAC Trial
Anti-Tumor Activity from Phase 1b PDAC Trial Historical comparison: Confirmed Response rate in P3 study of gemcitabine + nab-paclitaxel was 23%! All P1b Patients Confirmed Partial Response 6 (29%) Stable Disease 5 (24%) Progressive Disease 5 (24%) Not Evaluable 3 (14%) Not Applicable (died before an
Slide 32: P1b PDAC: Patients with Trough Levels >MEC Remain on Study Longer
P1b PDAC: Patients with Trough Levels >MEC Remain on Study Longer and Have Higher Response Rates Higher Batiraxcept Doses May be Needed to Saturate the Target and Increase Number of Patients with Trough Levels Above MEC ‘+ MEC High Patents MEC of batiraxcept in PDAC +203-001 i 21001 identified as 14
Slide 33: P1b PDAC: Better Clinical Outcomes in Patients who Achieve MEC
P1b PDAC: Better Clinical Outcomes in Patients who Achieve MEC Higher doses of batiraxcept are likely required in PDAC Best Response Partial Response 5 (56%) 1 (11%) Stable Disease 2 (22%) 2 (22%) Progressive Disease 0 4 (44%) NE 4 (11%) 2 (22%) NA (no scans) 411%) 0 Progression-Free Survival Censor
Slide 34: Market Research Suggests Batiraxcept Would Fill an Unmet Need (PDAC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm ” Efficacy in the base case is similar to FOLFIRINOX, | like that it is more tolerable for patients” Ifthe biomarker high population were really 70%, I would serum test and give [the
Slide 35: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Complete P3 proc fisaitaan P3 top-ine results _If positive, submit BLA Potential FDA approval Safety and preliminary 4. ecRCC eee eee re nal nation of P2rs Updated P1b/2a data Initiate dose escalation Updated data from wate P2a* sted) phase of P1b Pb dose escalation _
Slide 36: Financial Summary
Financial Summary $73.1 million* Cash and Cash Equivalents No Debt Cash Runway Expected to Fund Operations Into Late 2023
Slide 37: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases
Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Proprietary, differentiated first-in-class candidate inhibiting GAS6/AXL signaling pathway associated with tumor growth, metastasis, drug resistance, and poor survival rates | Batiraxcept has pot
Slide 38: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation November 2022 NASDAG: ARAV